Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Bladder Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 65 articles:
HTML format

Single Articles

    May 2020
  1. ADACHI A, Kawamura H, Yoshida D, Kawahara M, et al
    Whole-bladder Radiation Therapy for Lymph Node-negative Bladder Cancer With Muscle Invasion in Elderly Patients.
    Anticancer Res. 2020;40:2905-2909.
    PubMed     Abstract available

  2. HUANG CP, Liu LX, Shyr CR
    Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression.
    Anticancer Res. 2020;40:2715-2724.
    PubMed     Abstract available

    April 2020
  3. CHEN M, Chang WS, Shen TC, Gong CL, et al
    Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2020;40:2011-2017.
    PubMed     Abstract available

    March 2020
  4. YU J, Lu Y, Muto S, Ide H, et al
    The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis.
    Anticancer Res. 2020;40:1345-1357.
    PubMed     Abstract available

    December 2019
  5. LIU J, Li S, Cheng X, DU P, et al
    HOXB2 is a Putative Tumour Promotor in Human Bladder Cancer.
    Anticancer Res. 2019;39:6915-6921.
    PubMed     Abstract available

  6. LEE MY, Shi CS, Hsu YC, Huang KJ, et al
    Honokiol Is a Potential Therapeutic Agent and Has a Synergistic Effect With 5-FU in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2019;39:6555-6565.
    PubMed     Abstract available

    September 2019
  7. CHEN M, Tsai YT, Chang WS, Shih LC, et al
    Association of Caspase-8 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2019;39:4767-4773.
    PubMed     Abstract available

    August 2019
  8. AKITAKE M, Yamaguchi A, Shiota M, Imada K, et al
    Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2019;39:4325-4328.
    PubMed     Abstract available

    July 2019
  9. CHIANG CH, Yeh CY, Chung JG, Chiang IT, et al
    Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.
    Anticancer Res. 2019;39:3641-3649.
    PubMed     Abstract available

    May 2019
  10. NAKAMURA Y, Miyata Y, Takehara K, Asai A, et al
    The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.
    Anticancer Res. 2019;39:2317-2324.
    PubMed     Abstract available

    April 2019
  11. HANADA E, Kageyama S, Murai R, Kubota S, et al
    Pro-GA, a Novel Inhibitor of gamma-Glutamylcyclotransferase, Suppresses Human Bladder Cancer Cell Growth.
    Anticancer Res. 2019;39:1893-1898.
    PubMed     Abstract available

  12. HUANG AC, Cheng YD, Huang LH, Hsiao YT, et al
    Casticin Induces DNA Damage and Impairs DNA Repair in Human Bladder Cancer TSGH-8301 Cells.
    Anticancer Res. 2019;39:1839-1847.
    PubMed     Abstract available

    March 2019
  13. VASYUTIN I, Zerihun L, Ivan C, Atala A, et al
    Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling.
    Anticancer Res. 2019;39:1105-1118.
    PubMed     Abstract available

    February 2019
  14. KUSUHARA Y, Daizumoto K, Kawai K, Hirayama K, et al
    Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer.
    Anticancer Res. 2019;39:703-711.
    PubMed     Abstract available

  15. KUMAGAI-TOGASHI A, Uozaki H, Kikuchi Y, Watabe S, et al
    Tumorous CD10 Is More Strongly Related to the Progression of Urothelial Carcinoma than Stromal CD10.
    Anticancer Res. 2019;39:635-640.
    PubMed     Abstract available

    December 2018
  16. RADES D, Sondermann L, Motisi L, Janssen S, et al
    Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder.
    Anticancer Res. 2018;38:6841-6846.
    PubMed     Abstract available

    September 2018
  17. TSAI TH, Wang YM, Chang WS, Tsai CW, et al
    Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer.
    Anticancer Res. 2018;38:5159-5164.
    PubMed     Abstract available

  18. LEA MA, Kim H, desBORDES C
    Effects of Biguanides on Growth and Glycolysis of Bladder and Colon Cancer Cells.
    Anticancer Res. 2018;38:5003-5011.
    PubMed     Abstract available

    August 2018
  19. NAKAMURA R, Kakuhara H, Kikuchi K, Segawa T, et al
    Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer.
    Anticancer Res. 2018;38:4827-4831.
    PubMed     Abstract available

  20. TSAI KW, Kuo WT, Jeng SY
    Tight Junction Protein 1 Dysfunction Contributes to Cell Motility in Bladder Cancer.
    Anticancer Res. 2018;38:4607-4615.
    PubMed     Abstract available

  21. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
    Anticancer Res. 2018;38:4759-4766.
    PubMed     Abstract available

    July 2018
  22. GOUSSIA AC, Papoudou-Bai A, Charchanti A, Kitsoulis P, et al
    Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas.
    Anticancer Res. 2018;38:3985-3988.
    PubMed     Abstract available

    June 2018
  23. MOURMOURAS N, Philippou A, Christopoulos P, Kostoglou K, et al
    Differential Expression of IGF-I Transcripts in Bladder Cancer.
    Anticancer Res. 2018;38:3453-3459.
    PubMed     Abstract available

  24. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    PubMed     Abstract available

    May 2018
  25. REXIN P, Tauchert A, Hanze J, Heers H, et al
    The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.
    Anticancer Res. 2018;38:2749-2754.
    PubMed     Abstract available

  26. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    PubMed     Abstract available

    April 2018
  27. KIM S, Lee AJ, Yeo MK, Na YG, et al
    Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2018;38:2429-2437.
    PubMed     Abstract available

  28. MATSUNAGA W, Ichikawa M, Nakamura A, Ishikawa T, et al
    Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines.
    Anticancer Res. 2018;38:2015-2020.
    PubMed     Abstract available

  29. MAKINO T, Izumi K, Natsagdorj A, Iwamoto H, et al
    Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
    Anticancer Res. 2018;38:2241-2245.
    PubMed     Abstract available

    March 2018
  30. MIYATA Y, Matsuo T, Nakamura Y, Yasuda T, et al
    Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Anticancer Res. 2018;38:1629-1635.
    PubMed     Abstract available

  31. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Katzenwadel A, et al
    Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells.
    Anticancer Res. 2018;38:1369-1375.
    PubMed     Abstract available

    February 2018
  32. HEERS H, Gut JM, Hegele A, Hofmann R, et al
    Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
    Anticancer Res. 2018;38:833-837.
    PubMed     Abstract available

    January 2018
  33. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Abstract available

    December 2017
  34. CHEN CC, Huang CP, Tsai YT, Hseih TF, et al
    The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
    Anticancer Res. 2017;37:6893-6898.
    PubMed     Abstract available

  35. MINAMI S, Matsumoto K, Nagashio R, Hagiuda D, et al
    Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2017;37:6705-6714.
    PubMed     Abstract available

  36. SYRING I, Weiten R, Muller T, Schmidt D, et al
    The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.
    Anticancer Res. 2017;37:6685-6695.
    PubMed     Abstract available

    November 2017
  37. SCHINZARI G, Monterisi S, Pierconti F, Nazzicone G, et al
    Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Anticancer Res. 2017;37:6453-6458.
    PubMed     Abstract available

  38. LIAW CC, Chuang CK, Chang YH, Liao TY, et al
    Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
    Anticancer Res. 2017;37:6443-6451.
    PubMed     Abstract available

    October 2017
  39. AIZAWA R, Sakamoto M, Orito N, Kono M, et al
    The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.
    Anticancer Res. 2017;37:5761-5766.
    PubMed     Abstract available

  40. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.
    Anticancer Res. 2017;37:5603-5608.
    PubMed     Abstract available

  41. D'ANDREA D, Moschini M, Soria F, Gust KM, et al
    ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2017;37:5747-5753.
    PubMed     Abstract available

    September 2017
  42. CIMPEAN AM, Tarlui V, Cumpanas AA, Bolintineanu S, et al
    Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
    Anticancer Res. 2017;37:4935-4942.
    PubMed     Abstract available

  43. HSU FT, Sun CC, Wu CH, Lee YJ, et al
    Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.
    Anticancer Res. 2017;37:4919-4926.
    PubMed     Abstract available

    August 2017
  44. TANG X, Wang S, An C, DU P, et al
    Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer.
    Anticancer Res. 2017;37:4659-4663.
    PubMed     Abstract available

  45. ZHOU HH, Liu LY, Yu GH, Qu GM, et al
    Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
    Anticancer Res. 2017;37:4529-4537.
    PubMed     Abstract available

  46. DU P, Wang S, Tang X, An C, et al
    Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma.
    Anticancer Res. 2017;37:4499-4505.
    PubMed     Abstract available

    July 2017
  47. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients.
    Anticancer Res. 2017;37:3537-3541.
    PubMed     Abstract available

    June 2017
  48. JANSSEN S, Manig L, Schild SE, Rades D, et al
    Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.
    Anticancer Res. 2017;37:3287-3290.
    PubMed     Abstract available

    May 2017
  49. MANIG L, Kasmann L, Janssen S, Schild SE, et al
    Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer.
    Anticancer Res. 2017;37:2693-2696.
    PubMed     Abstract available

    April 2017
  50. SILVA J, Arantes-Rodrigues R, Pinto-Leite R, Faustino-Rocha AI, et al
    Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.
    Anticancer Res. 2017;37:1737-1745.
    PubMed     Abstract available

  51. KHANAL A, Budhathoki N, Singh VP, Shah BK, et al
    Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
    Anticancer Res. 2017;37:2033-2036.
    PubMed     Abstract available

    March 2017
  52. RADES D, Manig L, Janssen S, Schild SE, et al
    Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
    Anticancer Res. 2017;37:1485-1488.
    PubMed     Abstract available

  53. RADES D, Manig L, Janssen S, Schild SE, et al
    A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer.
    Anticancer Res. 2017;37:1481-1484.
    PubMed     Abstract available

  54. HUDOLIN T, Mengus C, Coulot J, Kastelan Z, et al
    Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
    Anticancer Res. 2017;37:1375-1380.
    PubMed     Abstract available

  55. SHI CS, Li JM, Chin CC, Kuo YH, et al
    Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2017;37:1149-1159.
    PubMed     Abstract available

    February 2017
  56. WIECZOREK E, Jablonowski Z, Tomasik B, Gromadzinska J, et al
    Different Gene Expression and Activity Pattern of Antioxidant Enzymes in Bladder Cancer.
    Anticancer Res. 2017;37:841-848.
    PubMed     Abstract available

  57. FRIEDMAN P, Lai JP
    Liver Metastasis of Urothelial Carcinoma with Hepatoid Features: An Unusual Morphological Finding.
    Anticancer Res. 2017;37:801-804.
    PubMed     Abstract available

    December 2016
  58. MANIG L, Kasmann L, Janssen S, Rades D, et al
    Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.
    Anticancer Res. 2016;36:6663-6665.
    PubMed     Abstract available

  59. HANCOCK BM, McGuire KL, Tsuji S, Reil K, et al
    A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
    Anticancer Res. 2016;36:6243-6248.
    PubMed     Abstract available

    October 2016
  60. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy.
    Anticancer Res. 2016;36:5519-5525.
    PubMed     Abstract available

  61. KRIEGMAIR MC, Balk M, Wirtz R, Steidler A, et al
    Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2016;36:5205-5213.
    PubMed     Abstract available

  62. IWAMOTO H, Izumi K, Shimura Y, Natsagdorj A, et al
    Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.
    Anticancer Res. 2016;36:5557-5561.
    PubMed     Abstract available

    September 2016
  63. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiotherapy for Muscle-invasive Bladder Cancer in Very Elderly Patients.
    Anticancer Res. 2016;36:4763-9.
    PubMed     Abstract available

  64. CHANG WS, Liao CH, Tsai CW, Hu PS, et al
    Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:4509-14.
    PubMed     Abstract available

    August 2016
  65. HAHN AW, Giri S, Pathak R, Bhatt VR, et al
    Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.
    Anticancer Res. 2016;36:4051-5.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.